Christopher P. Molineaux - 20 Jun 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
20 Jun 2023
Net transactions value
+$23,265
Form type
4
Filing time
22 Jun 2023, 16:32:22 UTC
Previous filing
20 Jun 2023
Next filing
04 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise $23,265 +16,500 +52% $1.41* 48,503 20 Jun 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (right to buy) Options Exercise $0 -16,500 -100% $0.000000* 0 20 Jun 2023 Common Stock 16,500 $1.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vested in twelve equal monthly installments commencing July 4, 2020, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.